Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.
Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.
复制标题
配对错配修复良好和缺陷的结直肠癌患者免疫学特征的比较
DOI:
10.1186/s12967-018-1570-z
复制
发表时间:
2018-07-13
影响因子:
7.4
通讯作者:
Xia LP
中科院分区:
文献类型:
--
作者:
Liu SS;Yang YZ;Jiang C;Quan Q;Xie QK;Wang XP;He WZ;Rong YM;Chen P;Yang Q;Yang L;Zhang B;Xia XJ;Kong PF;Xia LP
Background:Currently, mismatch repair-deficient (dMMR) status is a promising candidate for targeted immune checkpoint inhibition therapy in colorectal cancer (CRC) patients, however, the potential immunological mechanism has not yet been well clarified and some other predictors need to be excavated as well.Methods:We collected 330 CRC patients by the match of mismatch repair-proficient (167) and dMMR (163), explored the relationship between MMR status and some important immune molecules including MHC class I, CD3, CD4, CD8, CD56, programmed death-1 and programmed death ligand-1, and investigated the risk factors for dMMR status as well as low MHC class I expression. The Pearson Chi square test was used for analyzing the associations between clinicopathological and immune characteristics and MMR status, and two categories logistic regression model was used for univariate and multivariate analysis to predict the odds ratio of risk factors for dMMR status and low MHC class I expression.Results:Multivariate logistic regression analysis showed that low MHC class I and CD4 expression and high CD8 expression were significant risk factors for dMMR status [odds ratio (OR) = 24.66, 2.94 and 2.97, respectively; all p < 0.05] and dMMR status was the only risk factor for low MHC class I expression (OR = 15.34; p < 0.001).Conclusions:High CD8 and low MHC class I expression suggests the contradiction and complexity of immune microenvironment in dMMR CRC patients. Some other immunocytes such as CD56+cells might also participate in the process of immune checkpoint inhibition, whereas needs further investigations.
登录
查看更多内容
影响因子:
158.5
作者:
Hampel, H;Frankel, WL;Papadopoulos, N
通讯作者:
Papadopoulos, N
影响因子:
24.5
作者:
Simpson, Jonathan A. D.;Al-Attar, Ahmad;Durrant, Lindy G.
通讯作者:
Durrant, Lindy G.
DOI:
10.1158/1078-0432.ccr-15-0715
发表时间:
2016-01-15
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Sabbatino F;Villani V;Yearley JH;Deshpande V;Cai L;Konstantinidis IT;Moon C;Nota S;Wang Y;Al-Sukaini A;Zhu AX;Goyal L;Ting DT;Bardeesy N;Hong TS;Fernandez-del Castillo C;Tanabe KK;Lillemoe KD;Ferrone S;Ferrone CR
通讯作者:
Ferrone CR
影响因子:
28.2
作者:
Llosa, Nicolas J.;Cruise, Michael;Housseau, Franck
通讯作者:
Housseau, Franck
影响因子:
7.3
作者:
Paul S;Lal G
通讯作者:
Lal G